


SARS-CoV-2

# COVID-19 Pseudovirus Neutralizing Antibody Assay (Luciferase)


Catalog # KA6152      Size 1 Kit

## Applications




### Neutralization

SARS-CoV-2 spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7 and LALAPG 7F7, and then added into 293T-ACE cells.



### Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 µg or 20 µg COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 µg or 20 µg COVID-19 RBD SAM plus adjuvant (ppopV1).



### In vivo Neutralization

Hamsters received 2 doses of humanized monoclonal antibody 7F7 and then were infected with SARS-CoV-2 Pseudovirus Expressing Luciferase (Cat # U0401).

## Specification

### Product Description

COVID-19 Pseudovirus Neutralizing Antibody Assay (Luciferase) provides a highly sensitive and quantitative measurement of neutralizing antibodies.

<b>Supplied Product</b>	<p>Kit content:</p> <p>1 kit is sufficient for 100 assays in 24 well plates</p> <ol style="list-style-type: none"> <li>293T-hACE2 cell, 2x10<sup>6</sup>cells/vial, FBS with 10% DMSO</li> <li>SARS-CoV-2 Pseudovirus Expressing Luciferase</li> </ol>
<b>Materials Required But NOT Supplied</b>	<ol style="list-style-type: none"> <li>SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova</li> <li>ZymeFree™ Enzyme Free Cell Dissociation Reagent, Cat# TCL028-100ML, HIMEDIA</li> <li>DMEM culture medium containing 10% FBS (complete medium)</li> <li>Luciferase Assay System, Cat# E1500, Promega             <ol style="list-style-type: none"> <li>Luciferase Assay Substrate (lyophilized)</li> <li>Luciferase Assay Buffer</li> <li>Luciferase Cell Culture Lysis Reagent, 5X</li> </ol> </li> <li>TC-Treated 24 Well Plates, Cat# 3524, Corning</li> <li>OptiPlate™-96, Cat# 6005290, PerkinElmer</li> </ol>
<b>Suitable Sample</b>	<ol style="list-style-type: none"> <li>Immunized Serum</li> <li>Infected Serum</li> <li>Neutralizing Antibodies</li> <li>Peptide Inhibitors or Proteins</li> <li>Compounds Targeting Spike Induced Cell Fusion</li> </ol>
<b>Sample Volume</b>	10-50 uL (please check sample source)
<b>Assay Type</b>	Quantitative
<b>Detection Method</b>	Luciferase Activity
<b>Technology</b>	<a href="#">Pseudovirus</a>
<b>Regulatory Status</b>	For research use only (RUO)
<b>Storage Instruction</b>	<p>293T-hACE2 cell Store at liquid nitrogen.</p> <p>Pseudovirus Store at -80°C.</p> <p>Aliquot to avoid repeated freezing and thawing.</p>

## Applications

- Neutralization

SARS-CoV-2 spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7 and LALAPG 7F7, and then added into 293T-ACE cells.

- Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).

- *In vivo* Neutralization

Hamsters received 2 doses of humanized monoclonal antibody 7F7 and then were infected with SARS-CoV-2 Pseudovirus Expressing Luciferase (Cat # U0401).